Mabpharm (2181 HK)

Analysis

Industrials • Hong Kong

Mabpharm is a biopharmaceutical company specializing in the research, development, and manufacturing of monoclonal antibody drugs and biosimilars for cancer and autoimmune diseases. Its core products include CMAB009 Enlito, CMAB007 AomaiShu, and CMAB008 Leiting, which treat various conditions such as colorectal cancer, asthma, and rheumatoid arthritis. The company was founded in 2009 and is headquartered in Taizhou, Jiangsu, PRC.

Refresh

Exchange Announcement • 21 Sep 2026 16:34

2026 Interim Report

Exchange Announcement • 28 Aug 2026 21:04

Interim Results Announcement For The Six Months Ended June 30, 2026

Exchange Announcement • 17 Aug 2026 16:35

Date Of Board Meeting

Exchange Announcement • 26 Jun 2026 18:28

Third Amended And Restated Memorandum And Articles Of Association

Exchange Announcement • 26 Jun 2026 17:55

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

2026 Interim Report

Interim Results Announcement For The Six Months Ended June 30, 2026

Date Of Board Meeting

Third Amended And Restated Memorandum And Articles Of Association

Poll Results Of The Annual General Meeting Held On Friday, June 26, 2026